DOCSLIB.ORG

US 2019 / 0062735 A1 Welstead Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2019 / 0062735 A1 Welstead Et Al US 20190062735A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 / 0062735 A1 Welstead et al. ( 43 ) Pub. Date : Feb . 28 , 2019 ( 54 ) CRISPR - CPF1 -RELATED METHODS, (60 ) Provisional application No . 62/ 304 , 057, filed on Mar . COMPOSITIONS AND COMPONENTS FOR 4 , 2016 . CANCER IMMUNOTHERAPY ( 71 ) Applicant: EDITAS MEDICINE , INC ., Publication Classification CAMBRIDGE, MA (US ) (51 ) Int. CI. C12N 15 / 11 (2006 .01 ) ( 72 ) Inventors : Gordon Grant Welstead , Cambridge, C12N 9 /22 (2006 .01 ) MA (US ) ; Hariharan Jayaram , C12N 15 / 90 ( 2006 .01 ) Cambridge , MA (US ); Tongyao Wang , A61K 35 / 17 (2006 . 01) Malden , MA (US ) ; John Anthony (52 ) U . S . CI. Zuris , Cambridge, MA (US ) ; CPC .. .. C12N 15 / 11 ( 2013 .01 ) ; C12N 9 / 22 Christopher Borges, Reading , MA ( 2013 .01 ) ; C12N 15 / 907 (2013 . 01 ) ; C12N (US ) 2320 /32 (2013 . 01 ) ; C12N 2310 / 20 ( 2017 .05 ) ; (73 ) Assignee : EDITAS MEDICINE , INC . , C12N 2800 /80 (2013 . 01 ) ; A61K 35 / 17 CAMBRIDGE, MA (US ) (2013 .01 ) ( 21 ) Appl. No. : 16 /121 , 152 ( 22 ) Filed : Sep . 4 , 2018 (57 ) ABSTRACT Related U . S . Application Data CRISPR /Cpfl - related compositions and methods for treat (63 ) Continuation of application No . PCT/ US2017 / ment of cancer. 020598 , filed on Mar. 3 , 2017 . Specification includes a Sequence Listing . VIVUNIIKIZUIZIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII Direct repeat domain Targeting domain Patent Application Publication Feb . 28 , 2019 Sheet 1 of 8 US 2019 /0062735 A1 Targetingdomain FIG.1 Directrepeatdomain Patent Application Publication Feb . 28 , 2019 Sheet 2 of 8 US 2019 / 0062735 A1 100 LadderLadder ????? ? GWED539GWED539 171 GWED540 GWED541 . 8888888888888 GWED543GWED543 GWED544 GWED545 FIG.2 GWED546GWED546 02 * * GWED547 Ladder cutsize: GWED539142,331 146,327GWED540 GWED541190,283 GWED543184,289 159,314GWED544 189,284GWED545 96,377GWED546 157GWED547,136 CrRNAID:Expected FulllengthPCRProduct=450bp Patent Application Publication Feb . 28 , 2019 Sheet 3 of 8 US 2019 /0062735 A1 GWED549 GWED548 GWED547 GWED546 GWED545 LLLLLLLLLLLZTULTITITZIZ GWED544 IDCrRNA FIG.3A WIMMINIMIZ GWED543 GWED541 GWED540 GWED539 & qur?ayaDIIIIIIIIIIIZZZZZZZZZZZZZZINITIZIE ControlH2O negative ß / TCRa % Patent Application Publication Feb . 28 , 2019 Sheet 4 of 8 US 2019 / 0062735 A1 Will GWED539 KOMEX 0.76% TTTTTTTTTTTTT GWED546 20.2% FIG.3B EN GWED545 . 16.5% E Cpf1Alone 0.8% ??????? TCRA/B CD4 Patent Application Publication Feb . 28 , 2019 Sheet 5 of 8 US 2019 / 0062735 A1 / / / www. / / / GWED549 GWED548 GWED547 .ww GWED546 GWED545 ** ** *** ** CrRNAID FIG.4 www GWED544 GWED543 GWED541 . NNN GWED540 / *** / . /* / GWED539 ControlH2O Lymphocytes " Live " % Patent Application Publication Feb . 28 , 2019 Sheet 6 of 8 US 2019 / 0062735 A1 GWED549 GWED546 GWED545 CrRNAID FIG.5 GWED541 Uncut NHEJ % Patent Application Publication Feb . 28 , 2019 Sheet 7 of 8 US 2019 /0062735 A1 GWED546 GWED545 CrRNAID FIG.6 Cpf1alone b / TCR0 + CD4 of Frequency Patent Application Publication Feb . 28 , 2019 Sheet 8 of 8 US 2019 /0062735 A1 NH2 ????? FIG.7 ARCASTRUCTURE H2CO—?0P???2 ?????3 CH? + z — NH2 US 2019 /0062735 A1 Feb . 28 , 2019 CRISPR -CPF1 -RELATED METHODS , domains to a cytoplasmic effector domain . The effector COMPOSITIONS AND COMPONENTS FOR domain is typically derived from the CD3 -zeta chain of the CANCER IMMUNOTHERAPY T cell co - receptor complex , and can also include domains derived from CD28 and / or CD137 receptor proteins . The CROSS REFERENCE TO RELATED CAR extra -cellular domain binds the tumor antigen in an APPLICATIONS MHC - independent manner leading to T cell activation and 0001 ] This application is a Continuation of International proliferation , culminating in cytotoxic anti - tumor activity as described for TCR engineered T cells . Patent Application No . PCT /US17 /20598 filed Mar. 3 , 2017 , [0007 ] To date , at least 15 different tumor antigens have which claims priority to U . S . Provisional Application No . been targeted in clinical trials of engineered T cells . In 62 / 304 ,057 , filed Mar. 4 , 2016 , the contents of each of which several trials , anti - tumor activity has been reported . The are incorporated by reference in their entireties herein , and greatest success has been achieved in hematologic malig priority to each of which is claimed . nancies. For example , adoptive transfer of CAR - T cells engineered to target the B cell antigen , CD19 , led to multiple SEQUENCE LISTING partial and complete responses in subjects with lymphoma, [ 0002 ] The specification further incorporates by reference acute lymphoblastic leukemia , acute lymphocytic leukemia the Sequence Listing submitted herewith via EFS on Sep . 4 , and B - cell acute lymphocytic leukemia . In contrast , trials 2018 . Pursuant to 37 C . F . R . § 1 .52 ( e ) (5 ) , the Sequence targeting other tumor types , especially solid tumors , includ Listing text file , identified as 0841770198SL2. txt , is 738 , ing renal cell carcinoma , neuroblastoma, colorectal cancer, 470 bytes and was created on Nov . 14 , 2018 . The entire breast cancer, ovarian cancer , melanoma, sarcoma and pros contents of the Sequence Listing are hereby incorporated by tate cancer , have been less successful. In many of these reference . The Sequence Listing does not extend beyond the trials , very few patients experienced objective responses . scope of the specification and thus does not contain new Thus , there is a need to improve the anti - tumor efficacy of matter . adoptively transferred engineered T cells . FIELD OF THE PRESENTLY DISCLOSED SUMMARY OF THE PRESENTLY DISCLOSED SUBJECT MATTER SUBJECT MATTER [0003 ] The invention relates to CRISPR / Cpf1 - related [ 0008 ] Methods and compositions disclosed herein pro methods, compositions and components for editing a target vide for the treatment of cancer using an immunotherapy nucleic acid sequence, or modulating expression of a target approach comprising administration of genetically engi nucleic acid sequence , and applications thereof in connec neered T cells or T cell precursors to a subject. An approach tion with cancer immunotherapy comprising adoptive trans to treat a subject suffering from cancer is to isolate T cells fer of engineered T cells or T cell precursors. from the subject, genetically modify them to target an antigen expressed by the cancer cells , then re - introduce them BACKGROUND into the subject ; a process referred to as adoptive T cell [ 0004 ] Adoptive transfer of genetically engineered T cells transfer. Methods to genetically modify T cells include has entered clinical testing as a cancer therapeutic modality . introduction of T cell receptor ( TCR ) or chimeric antigen Typically , the approach consists of the following steps : 1 ) receptor (CAR ) genes encoding trans -membrane TCR or obtaining leukocytes from the subject by apheresis ; 2 ) CAR proteins, respectively , which specifically recognize selecting / enriching for T cells ; 3 ) activating the T cells by particular cancer antigens . In certain embodiments , engage cytokine treatment; 4 ) introducing cloned T cell receptor ment of the tumor - expressed antigen with the antigen bind ( TCR ) genes or a chimeric antigen receptor (CAR ) gene by ing domain of the TCR or CAR protein initiates a signaling retroviral transduction , lentiviral transduction or electropo cascade leading to T cell activation , proliferation and , ulti ration ; 5 ) expanding the T cells by cytokine treatment ; 6 ) mately , destruction of the cancer cell via a cytotoxic immune conditioning the subject, usually by lymphodepletion ; and 7 ) response (Kershaw et al. , 2013 NatRevCancer 13 , 525 -541 ) . infusion of the engineered T cells into the subject. [0009 ] Adoptive T cell transfer utilizing genetically modi [ 0005 ] Sources of cloned TCR genes (TRAC and TRBC ) fied T cells has entered clinical testing as a therapeutic for include rare T cell populations isolated from individuals solid and hematologic malignancies. Results to date have with particular malignancies and T cell clones isolated from been mixed . In hematologic malignancies ( especially lym T cell receptor -humanized mice immunized with specific phoma, Chronic lymphocytic leukemia (CLL ) and Acute tumor antigens or tumor cells . Following adoptive transfer, lymphocytic leukemia ( ALL ) ) , the majority of patients in TCR - engineered T cells recognize their cognate antigen several Phase 1 and 2 trials exhibited at least a partial peptides presented by major histocompatibility complex response , with some exhibiting complete responses (MHC ) proteins on the tumor cell surface . Antigen engage (Kochenderfer , J . N . et al. , 2012 Blood 119 , 2709 -2720 ) . ment stimulates signal transduction pathways leading to T However, in most tumor types ( including melanoma, renal cell activation and proliferation . Stimulated T cells then cell carcinoma and colorectal cancer ) , fewer responses have mount a cytotoxic anti - tumor cell response , typically involv been observed ( Johnson , L . A . et al. , 2009 Blood 114 , ing a secreted complex comprising Granzyme B , perforin 535 - 546 ; Lamers , C . H . et al. , 2013 Mol. Ther . 21, 904 -912 ; and granulysin , inducing tumor cell apoptosis . Warren , R . S . et al ., 1998 Cancer Gene Ther. 5 , S1- S2 ) . [ 0006 ] Chimeric antigen receptor (CAR ) genes encode Thus , there exists a need to improve the efficacy of adoptive artificial T cell receptors comprising an extra - cellular tumor transfer of modified T cells in cancer treatment
Load more

Recommended publications
  • A Novel Type of SYT/SSX Fusion
    A Novel Type of SYT/SSX Fusion: Methodological and Biological Implications Maria Törnkvist, M.Sc., Bertha Brodin, Ph.D., Armando Bartolazzi, M.D., Ph.D., Olle Larsson, M.D., Ph.D. Department of Cellular and Molecular Tumor Pathology, Cancer Centrum Karolinska, Karolinska Hospital (MT, BB, AB, OL), Stockholm, Sweden; and Department of Pathology, Regina Elena Cancer Institute (AB), Rome, Italy the presence of SYT/SSX transcripts in two cases Synovial sarcoma (SS) is a rare soft-tissue tumor using the proposed RT-PCR approach. Applications that affects children and young adults. It is charac- of optimized RT-PCR can contribute to reduce false- terized by the chromosomal translocation t(X; negative SYT/SSX SS cases reported in literature. 18)(p11.2;q11.2), which results in the fusion of the SYT gene on chromosome 18 with a SSX gene on KEY WORDS: RT-PCR, Synovial sarcoma, SYT/SSX chromosome X. In the majority of cases, SYT is fusion gene, SYT/SSX variants. fused to exon 5 of SSX1 (64%), SSX2 (36%), or, Mod Pathol 2002;15(6):679–685 rarely, SSX4. A novel fusion transcript variant deriv- ing from the fusion of SYT to exon 6 of SSX4 gene Synovial sarcomas (SS) account for 7 to 10% of all (SYT/SSX4v) was found coexpressed in one of the human soft-tissue sarcomas and are mainly located previously reported SYT/SSX4 cases. In the present in the extremities in the vicinity of large joints (1). investigation, we describe a new SS case that was Depending on histomorphological appearance, SSs previously shown to be negative for SYT/SSX1 and are usually subdivided into two major forms, bipha- SYT/SSX2 expression by conventional reverse tran- sic and monophasic.
    [Show full text]
  • The “Melanoma-Enriched” Microrna Mir-4731-5P Acts As a Tumour Suppressor
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 31 Research Paper The “melanoma-enriched” microRNA miR-4731-5p acts as a tumour suppressor Mitchell S. Stark1,2, Lisa N. Tom1, Glen M. Boyle2, Vanessa F. Bonazzi3, H. Peter Soyer1, Adrian C. Herington3, Pamela M. Pollock3, Nicholas K. Hayward2 1Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, QLD, Australia 2QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD, Australia 3School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, at The Translational Research Institute, Brisbane, QLD, Australia Correspondence to: Mitchell S. Stark, email: [email protected] Keywords: SSX, microRNA, melanoma, PMP22, miR-4731 Received: May 02, 2015 Accepted: June 01, 2016 Published: June 16, 2016 ABSTRACT We previously identified miR-4731-5p (miR-4731) as a melanoma-enriched microRNA following comparison of melanoma with other cell lines from solid malignancies. Additionally, miR-4731 has been found in serum from melanoma patients and expressed less abundantly in metastatic melanoma tissues from stage IV patients relative to stage III patients. As miR-4731 has no known function, we used biotin-labelled miRNA duplex pull-down to identify binding targets of miR- 4731 in three melanoma cell lines (HT144, MM96L and MM253). Using the miRanda miRNA binding algorithm, all pulled-down transcripts common to the three cell lines (n=1092) had potential to be targets of miR-4731 and gene-set enrichment analysis of these (via STRING v9.1) highlighted significantly associated genes related to the ‘cell cycle’ pathway and the ‘melanosome’. Following miR-4731 overexpression, a selection (n=81) of pull-down transcripts underwent validation using a custom qRT-PCR array.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Product Sheet CA1235
    SSX2 Antibody Applications: WB, IHC Detected MW: 25 kDa Cat. No. CA1235 Species & Reactivity: Human, Mouse, Rat Isotype: Rabbit IgG BACKGROUND SSX2 belongs to the family of highly homologous based immunotherapy.4 Two transcript variants synovial sarcoma X (SSX) breakpoint proteins. encoding distinct isoforms have been identified for The SSX gene family is composed of at least 9 SSX2 gene. SSX2 is thought to function in functional and highly homologous members and development and germ line cells as a repressive shown to be located on chromosome X. The gene regulator. Its control of gene expression is normal testis expresses SSX1, 2, 3, 4, 5, and 7, believed to be epigenetic in nature and to involve but not 6, 8, or 9. In tumors, SSX1, 2, and 4 are chromatin modification and remodeling. It is most expressed at varying frequencies, whereas SSX3, likely mediated by the association of SSX2 with the 5, and 6 are rarely expressed. In addition, no Polycomb gene silencing complex at the SSXRD expression of SSX8, or 9 has been observed. SSX1 domain. Polycomb silencing involves chromatin to SSX5 are also normally expressed in thyroid.1 compaction, DNA methylation, repressive histone The SSX family shares nucleotide homology modifications and inaccessibility of promoter ranging from 88% to 95%, and amino acid regions to transcription machineries. Other SSX2- homology ranging from 77% to 91%. The NH2- interacting partners include the LIM homeobox terminal moieties of the SSX proteins exhibit protein LHX4, a Ras-like GTPase Interactor, homology to the Krüppel-associated box (KRAB) RAB3IP thought to be involved in vesicular domain, a domain that is known to be involved in transport, and SSX2IP, a putative cell transcriptional repression.
    [Show full text]
  • Genome-Wide Analysis of Cancer/Testis Gene Expression
    Genome-wide analysis of cancer/testis gene expression Oliver Hofmanna,b,1, Otavia L. Caballeroc, Brian J. Stevensond,e, Yao-Tseng Chenf, Tzeela Cohenc, Ramon Chuac, Christopher A. Maherb, Sumir Panjib, Ulf Schaeferb, Adele Krugerb, Minna Lehvaslaihob, Piero Carnincig,h, Yoshihide Hayashizakig,h, C. Victor Jongeneeld,e, Andrew J. G. Simpsonc, Lloyd J. Oldc,1, and Winston Hidea,b aDepartment of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, SPH2, 4th Floor, Boston, MA 02115; bSouth African National Bioinformatics Institute, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa; cLudwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; dLudwig Institute for Cancer Research, Lausanne Branch, 1015 Lausanne, Switzerland; eSwiss Institute of Bioinformatics, 1015 Lausanne, Switzerland; fWeill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021; gGenome Exploration Research Group (Genome Network Project Core Group), RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan; and hGenome Science Laboratory, Discovery Research Institute, RIKEN Wako Institute, 2-1 Hirosawa, Wako, Saitama, 3510198, Japan Contributed by Lloyd J. Old, October 28, 2008 (sent for review June 6, 2008) Cancer/Testis (CT) genes, normally expressed in germ line cells but expression profile information frequently limited to the original also activated in a wide range of cancer types, often encode defining articles. In some cases, e.g., ACRBP, the original antigens that are immunogenic in cancer patients, and present CT-restricted expression in normal tissues could not be con- potential for use as biomarkers and targets for immunotherapy.
    [Show full text]
  • Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte As Tumorigenic Precursor and DMRT1 As Candidate Chromosome 9 Gene
    Research Article Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene Leendert H.J. Looijenga,1 Remko Hersmus,1 Ad J.M. Gillis,1 Rolph Pfundt,4 Hans J. Stoop,1 Ruud J.H.L.M. van Gurp,1 Joris Veltman,1 H. Berna Beverloo,2 Ellen van Drunen,2 Ad Geurts van Kessel,4 Renee Reijo Pera,5 Dominik T. Schneider,6 Brenda Summersgill,7 Janet Shipley,7 Alan McIntyre,7 Peter van der Spek,3 Eric Schoenmakers,4 and J. Wolter Oosterhuis1 1Department of Pathology, Josephine Nefkens Institute; Departments of 2Clinical Genetics and 3Bioinformatics, Erasmus Medical Center/ University Medical Center, Rotterdam, the Netherlands; 4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; 5Howard Hughes Medical Institute, Whitehead Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts; 6Clinic of Paediatric Oncology, Haematology and Immunology, Heinrich-Heine University, Du¨sseldorf, Germany; 7Molecular Cytogenetics, Section of Molecular Carcinogenesis, The Institute of Cancer Research, Sutton, Surrey, United Kingdom Abstract histochemistry, DMRT1 (a male-specific transcriptional regulator) was identified as a likely candidate gene for Spermatocytic seminomas are solid tumors found solely in the involvement in the development of spermatocytic seminomas. testis of predominantly elderly individuals. We investigated these tumors using a genome-wide analysis for structural and (Cancer Res 2006; 66(1): 290-302) numerical chromosomal changes through conventional kar- yotyping, spectral karyotyping, and array comparative Introduction genomic hybridization using a 32 K genomic tiling-path Spermatocytic seminomas are benign testicular tumors that resolution BAC platform (confirmed by in situ hybridization).
    [Show full text]
  • Faculty of Graduate Studies and Scientific Research Molecular
    Republic of Sudan Ministry of Higher Education and Scientific Research Shendi University Faculty of Graduate Studies and Scientific Research Molecular Identification of Genetic Markers of Susceptibility to Essential Hypertension Using Whole Exome Sequencing among Sudanese Patients from Afro- Asiatic and Nilo-Saharan ethnic groups A Thesis Submitted in Fulfillment for the Requirements of PhD Degree in Biochemistry By: Wesal Ahmed ELHanbli Babiker MBBS- MSc Medical Biochemistry Supervisor: Dr: Dina Ahmed Hassan Associate professor of Biochemistry (2020) سورة الفاتحة I Bibliographic Entry Author: Wesal Ahmed ELHanbli Babiker Thesis: Molecular Identification of Genetic Markers of Susceptibility to Essential Hypertension Using Whole Exome Sequencing among Sudanese Patients from Afro-asiatic and Nilo-Saharan ethnic groups Degree program: PhD Faculty: Faculty of Medicine Field of study: Biochemistry Supervisor: Dr: Dina Ahmed Hassan Duration: (from 2015 to 2020) Key words: Essential hypertension, whole exome sequencing, bioinformatics tools, GPCR, MTHFR, ADM, Real-time PCR. II PhD Examination Committee Members Thesis Title: Molecular Identification of Genetic Markers of Susceptibility to Essential Hypertension Using Whole Exome Sequencing among Sudanese Patients from Afro-asiatic and Nilo-Saharan ethnic groups Supervisor: Dr: Dina Ahmed Hassan Signature …………………………… date ……………………………. Internal Examiner: Prof. Rashid Eltayeb Abdalla Signature …………………………….. date …………………………… External Examiner: Prof. Mamoun Makki EL Manna Signature …………………………….. date ……………………………. III Statement I Wesal Ahmed ELHanbli Babiker, declare that the study of Molecular Identification of Genetic Markers of Susceptibility to Essential Hypertension Using Whole Exome Sequencing among Sudanese Patients from Afro-asiatic and Nilo- Saharan ethnic groups, is my own original work and submitted in fulfillment for the requirements of PhD degree in biochemistry. I have followed all ethical and technical principles in the preparation, data collection, data analysis and compilation of this study.
    [Show full text]
  • SSX5 Mouse Monoclonal Antibody [Clone ID: OTI1H1] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for CF504223 SSX5 Mouse Monoclonal Antibody [Clone ID: OTI1H1] Product data: Product Type: Primary Antibodies Clone Name: OTI1H1 Applications: WB Recommended Dilution: WB 1:2000 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human SSX5(NP_066295) produced in HEK293T cell. Formulation: Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose) Reconstitution Method: For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific) Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 26.1 kDa Gene Name: Homo sapiens SSX family member 5 (SSX5), transcript variant 1, mRNA. Database Link: NP_066295 Entrez Gene 6758 Human O60225 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 SSX5 Mouse Monoclonal Antibody [Clone ID: OTI1H1] – CF504223 Background: The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins.
    [Show full text]
  • Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis
    Author Manuscript Published OnlineFirst on August 31, 2011; DOI: 10.1158/0008-5472.CAN-11-2127 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer Heath A. Smith, Robert J. Cronk, Joshua M. Lang, and Douglas G. McNeel* Departments of Medicine and Oncology, University of Wisconsin-Madison, Madison, WI, 53705, USA * To whom correspondence should be addressed: 7007 Wisconsin Institutes for Medical Research, 1111 Highland Ave. Madison, WI 53705. Tel: (608) 265-8131 Fax: (608) 265-0614 Running Title: Expression of the SSX CTA in Prostate Cancer Key Words: SSX, CTA, Prostate Cancer, 5-Aza-2'-deoxycytidine, Trichostatin A Abbreviations: SSX, synovial sarcoma chromosome X breakpoint; CTA, cancer testis antigen; TAA, tumor associated antigen; RT-PCR, reverse transcription polymerase chain reaction; qRT-PCR, quantitative reverse transcription polymerase chain reaction; MHC, major histocompatibility complex; ELISPOT, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; 5-aza-dc, 5-Aza-2'-deoxycytidine; TSA, Trichostatin A; CTL, cytotoxic T lymphocyte; PAGE, polyacrylamide gel electrophoresis; IHC, immunohistochemistry; SFU, spot-forming units; EMA, epigenetic modifying agent Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 31, 2011; DOI: 10.1158/0008-5472.CAN-11-2127 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Recent FDA approval of the first immunotherapy for prostate cancer encourages efforts to improve immune targeting of this disease. The synovial sarcoma X chromosome breakpoint (SSX) proteins comprise a set of cancer-testis antigens (CTA) that are upregulated in MHC class I-deficient germline cells and in various types of advanced cancers with a poor prognosis.
    [Show full text]
  • Genome-Wide Gene Expression Profiling of Randall's Plaques In
    CLINICAL RESEARCH www.jasn.org Genome-Wide Gene Expression Profiling of Randall’s Plaques in Calcium Oxalate Stone Formers † † Kazumi Taguchi,* Shuzo Hamamoto,* Atsushi Okada,* Rei Unno,* Hideyuki Kamisawa,* Taku Naiki,* Ryosuke Ando,* Kentaro Mizuno,* Noriyasu Kawai,* Keiichi Tozawa,* Kenjiro Kohri,* and Takahiro Yasui* *Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; and †Department of Urology, Social Medical Corporation Kojunkai Daido Hospital, Daido Clinic, Nagoya, Japan ABSTRACT Randall plaques (RPs) can contribute to the formation of idiopathic calcium oxalate (CaOx) kidney stones; however, genes related to RP formation have not been identified. We previously reported the potential therapeutic role of osteopontin (OPN) and macrophages in CaOx kidney stone formation, discovered using genome-recombined mice and genome-wide analyses. Here, to characterize the genetic patho- genesis of RPs, we used microarrays and immunohistology to compare gene expression among renal papillary RP and non-RP tissues of 23 CaOx stone formers (SFs) (age- and sex-matched) and normal papillary tissue of seven controls. Transmission electron microscopy showed OPN and collagen expression inside and around RPs, respectively. Cluster analysis revealed that the papillary gene expression of CaOx SFs differed significantly from that of controls. Disease and function analysis of gene expression revealed activation of cellular hyperpolarization, reproductive development, and molecular transport in papillary tissue from RPs and non-RP regions of CaOx SFs. Compared with non-RP tissue, RP tissue showed upregulation (˃2-fold) of LCN2, IL11, PTGS1, GPX3,andMMD and downregulation (0.5-fold) of SLC12A1 and NALCN (P,0.01). In network and toxicity analyses, these genes associated with activated mitogen- activated protein kinase, the Akt/phosphatidylinositol 3-kinase pathway, and proinflammatory cytokines that cause renal injury and oxidative stress.
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Identification of a Novel Spliced Variant of the SYT Gene Expressed in Normal Tissues and in Synovial Sarcoma
    British Journal of Cancer (2001) 84(8), 1087–1094 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2001.1710, available online at http://www.idealibrary.com on http://www.bjcancer.com Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma E Tamborini1, V Agus1, A Mezzelani1, C Riva1, G Sozzi2, A Azzarelli3, MA Pierotti2 and S Pilotti1 1Department of Pathology, 2Department of Experimental Oncology, 3Department of Musculo-Skeletal Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1 20133 Milano, Italy Summary Synovial sarcoma (SS) is cytogenetically characterized by the translocation t(X;18)(p11.2-q11.2) generating a fusion between the SYT gene on chromosome 18 and one member of the SSX family gene (SSX1; SSX2; SSX4) on chromosome X. Here, we report for the first time that 2 forms of SYT mRNA are present in both normal tissues and SSs. By amplifying the full-length SYT cDNA of two SSs, we detected 2 bands, here designated N-SYT and I-SYT. The latter, previously undescribed, contains an in-frame insertion of 93 bp. Its sequencing revealed a 100% homology with the mouse SYT gene. These two SYT forms were present, although in different amounts, in all human normal tissues examined, including kidney, stomach, lung, colon, liver and synovia. Coexistence of N-SYT and I-SYT (both fused with SSX) was detected in a series of 59 SSs (35 monophasic and 24 biphasic) and in a SS cell line. A preliminary analysis of the differential expression levels of N-SYT and I-SYT in SSs revealed that the latter was consistently overexpressed, suggesting a role in SS pathogenesis.
    [Show full text]